Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01193348
Registration number
NCT01193348
Ethics application status
Date submitted
31/08/2010
Date registered
1/09/2010
Date last updated
29/04/2015
Titles & IDs
Public title
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Query!
Scientific title
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Query!
Secondary ID [1]
0
0
C10-003
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
aHUS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Atypical Hemolytic-Uremic Syndrome
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Blood
0
0
0
0
Query!
Anaemia
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Eculizumab
Experimental: Eculizumab -
Treatment: Drugs: Eculizumab
Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of Patients With Complete TMA Response
Query!
Assessment method [1]
0
0
Proportion of Patients with Complete TMA response was determined and defined by normalization of hematological parameters (platelet count and LDH) and = 25% improvement in serum creatinine from baseline which was sustained for at least two consecutive measurements obtained at least four weeks apart).
Query!
Timepoint [1]
0
0
Through 26 weeks
Query!
Secondary outcome [1]
0
0
Proportion of Patients With Complete Hematologic Response
Query!
Assessment method [1]
0
0
Proportion of Patients with Complete Hematologic response through 26 weeks of treatment was determined and defined by normalization of platelet count and LDH sustained for at least two consecutive measurements obtained at least four weeks apart.
Query!
Timepoint [1]
0
0
Through 26 weeks
Query!
Secondary outcome [2]
0
0
Proportion of Patients With Platelet Count Normalization
Query!
Assessment method [2]
0
0
Proportion of Patients with Platelet Count Normalization through 26 weeks of treatment was determined and defined as the platelet count observed to be = 150 x 109/L on at least two consecutive measurements which span a period of at least four weeks.
Query!
Timepoint [2]
0
0
Through 26 weeks
Query!
Secondary outcome [3]
0
0
Proportion of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement
Query!
Assessment method [3]
0
0
Proportion of Patients with Estimated Glomerular Filtration Rate (eGFR) Improvement was determined and defined as an increase in eGFR by = 15 mL/min/1.73m2 from baseline, sustained for at least two consecutive measurements obtained at least four weeks apart.
Query!
Timepoint [3]
0
0
Through 26 weeks
Query!
Secondary outcome [4]
0
0
Platelet Count Change From Baseline to 26 Weeks
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Through 26 weeks
Query!
Secondary outcome [5]
0
0
Proportion of Patients With Complete TMA Response
Query!
Assessment method [5]
0
0
Proportion of Patients with Complete TMA response was determined and defined by normalization of hematological parameters (platelet count and LDH) and = 25% improvement in serum creatinine from baseline which was sustained for at least two consecutive measurements obtained at least four weeks apart).
Query!
Timepoint [5]
0
0
Through End of Study, Median Exposure 55 Weeks
Query!
Secondary outcome [6]
0
0
Proportion of Patients With Complete Hematologic Response
Query!
Assessment method [6]
0
0
Proportion of Patients with Complete Hematologic response through end of study was determined and defined by normalization of platelet count and LDH sustained for at least two consecutive measurements obtained at least four weeks apart.
Query!
Timepoint [6]
0
0
Through End of Study, Median Exposure 55 Weeks
Query!
Secondary outcome [7]
0
0
Proportion of Patients With Platelet Count Normalization
Query!
Assessment method [7]
0
0
Proportion of Patients with Platelet Count Normalization through end of study was determined and defined as the platelet count observed to be = 150 x 109/L on at least two consecutive measurements which span a period of at least four weeks
Query!
Timepoint [7]
0
0
Through End of Study, Median Exposure 55 Weeks
Query!
Secondary outcome [8]
0
0
Proportion of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement
Query!
Assessment method [8]
0
0
Proportion of Patients with Estimated Glomerular Filtration Rate (eGFR) Improvement was determined and defined as an increase in eGFR by = 15 mL/min/1.73m2 from baseline, sustained for at least two consecutive measurements obtained at least four weeks apart.
Query!
Timepoint [8]
0
0
Through End of Study, Median Exposure 55 Weeks
Query!
Secondary outcome [9]
0
0
Platelet Count Change From Baseline to 52 Weeks
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Through 52 Weeks
Query!
Secondary outcome [10]
0
0
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 5 - <10kg) N=3
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Induction Phase was between 1 and 4 weeks in length depending on patient weight cohort.Maintenance Phase was started 1 week after induction phase and dosing of eculizumab administration was every 2 weeks or every 3 weeks depending on patient weight cohort
Query!
Secondary outcome [11]
0
0
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 10 - <20kg) N=7
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Induction Phase was between 1 and 4 weeks in length depending on patient weight cohort.Maintenance Phase was started 1 week after induction phase and dosing of eculizumab administration was every 2 weeks or every 3 weeks depending on patient weight cohort
Query!
Secondary outcome [12]
0
0
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 20 - <30kg)
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Induction Phase was between 1 and 4 weeks in length depending on patient weight cohort. Maintenance Phase was started either 2 weeks or 3 weeks after induction phase depending on patient weight cohort
Query!
Secondary outcome [13]
0
0
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 30 - <40kg) N=1
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Induction Phase was between 1 and 4 weeks in length depending on patient weight cohort. Maintenance Phase was started either 2 weeks or 3 weeks after induction phase depending on patient weight cohort
Query!
Secondary outcome [14]
0
0
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort =40kg) N=5
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Induction Phase was between 1 and 4 weeks in length depending on patient weight cohort. Maintenance Phase was started either 2 weeks or 3 weeks after induction phase depending on patient weight cohort
Query!
Eligibility
Key inclusion criteria
Inclusion:
1. Patient's parent/legal guardian must have been willing and able to give written informed consent and the patient must have been willing to give written informed assent (if applicable as determined by the central IRB/IEC).
2. Pediatric patients with aHUS: Patients could have been newly diagnosed, or with previously diagnosed disease, or post-kidney transplant with the disease.
3. Patients one month to 18 years and body weight = 5kg.
4. Platelet count at screening and baseline visit must have been below lower limit of normal (<LLN). If screening visit and baseline visit are combined into one day, an additional platelet count value obtained at least 24 hours before screening/baseline sample must also be <LLN.
5. Exhibited signs or symptoms of hemolysis at start of current aHUS event (i.e., lactate dehydrogenase (LDH) =1.5 x Upper Limit of Normal [ULN] and hemoglobin =LLN), fragmented RBC with a negative Coombs test.
6. Serum Creatinine level =97 percentile for age at screening (patients requiring dialysis for acute renal failure are also eligible).
7. Patients with aHUS due to complement regulatory protein genetic abnormality or anti-complement factor antibody or those in whom known etiologies of hemolytic uremic syndrome (HUS) have been ruled out as confirmed in the
Query!
Minimum age
1
Month
Query!
Query!
Maximum age
18
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria.
8. Patients must have been vaccinated against N. meningitidis, pneumococcus and haemophilus (per the vaccine label) at least 14 days prior to study drug initiation or otherwise be protected by prophylactic antibiotics. Patients under age two years were to receive antibiotic prophylaxis throughout the treatment period.
9. Female patients of childbearing potential (female patients who have achieved menarche) must have been practicing an effective, reliable and medically approved contraceptive regimen during the entire duration of the study, including the follow-up period. At the time of the last follow-up visit, patients must have agreed to continue to use adequate contraception methods for up to five months following discontinuation of eculizumab treatment.
10. Able and willing to comply with study procedures
Exclusion:
Any of the following was regarded as a criterion for exclusion from the study:
1. Known familial ADAMTS-13 deficiency (ADAMTS-13 <5%).
2. Shiga toxin E.coli-related hemolytic uremic syndrome (STEC-HUS [known Shiga toxin + E.coli]).
3. History of malignancy within five years of screening.
4. Known human immunodeficiency virus (HIV) infection.
5. Identified drug exposure-related HUS.
6. Infection-related HUS.
7. HUS related to bone marrow transplant (BMT).
8. HUS related to vitamin B12 deficiency.
9. Known Systemic Lupus Erythematosus (SLE) or antiphospholipid antibody positivity or syndrome.
10. Plasma Therapy for >5 weeks prior to enrollment.
11. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for end-stage renal disease [ESRD]).
12. Patients with a confirmed diagnosis of sepsis defined as positive blood cultures within seven days of the screening visit and not treated with antibiotics to which the organism is sensitive.
13. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the Investigator confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS disease.
14. Pregnancy or lactation.
15. History of meningococcal/pneumococcal/gonococcal disease.
16. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.
17. Patients receiving chronic intravenous immunoglobulin (IVIg) within eight weeks unless for unrelated medical condition (e.g., Hypogammaglobinemia), or chronic Rituximab therapy within 12 weeks of the screening visit.
18. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors, calcineurin inhibitors (e.g., cyclosporine or tacrolimus are excluded unless: [1] part of an established post-transplant anti-rejection regime, or [2] patient has confirmed anti-Complement Factor antibodies antibody requiring immunosuppressive therapy or [3] steroids are being used for a condition other than aHUS (example asthma).
19. Participation in any other investigational drug trial or device trial, or procedures beginning four weeks prior to screening and throughout the entire trial
20. Prior use of eculizumab, hypersensitivity to eculizumab, to murine proteins or to one of the excipients.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
22
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
0
0
- North Adelaide
Query!
Recruitment postcode(s) [1]
0
0
5006 - North Adelaide
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
New Jersey
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Texas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Washington
Query!
Country [5]
0
0
Belgium
Query!
State/province [5]
0
0
Gent
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Ontario
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Lille
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Marseille
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Paris
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Rouen
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Hannover
Query!
Country [12]
0
0
Italy
Query!
State/province [12]
0
0
Milano
Query!
Country [13]
0
0
Italy
Query!
State/province [13]
0
0
Palermo
Query!
Country [14]
0
0
Netherlands
Query!
State/province [14]
0
0
Nijmegen
Query!
Country [15]
0
0
United Kingdom
Query!
State/province [15]
0
0
London
Query!
Country [16]
0
0
United Kingdom
Query!
State/province [16]
0
0
Nottingham
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Alexion Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary purpose is to assess the efficacy and safety of eculizumab in pediatric patients with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal impairment.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01193348
Query!
Trial related presentations / publications
Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD012862. doi: 10.1002/14651858.CD012862.pub2. Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol. 2011 Nov;26(11):2085-8. doi: 10.1007/s00467-011-1989-4. Epub 2011 Aug 30.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01193348
Download to PDF